Deputy Minister Reginah Mhaule: Launch of Education plus initiative

Keynote address by the Deputy Minister of Basic Education, Dr Reginah Mhaule, MP, at the launch of the Education plus initiative

Programme Director

Ms Christine Muhigana representing the United Nations Resident Coordinator Esteemed Representatives from United Nations Agencies in South Africa:

UNAIDS

UNESCO

UNFPA

UNICEF

UN-Women

SANAC Co-Chair, Ms Steve Letsike SANAC CEO, Dr Thembi Xulu

Mrs Palesa Tyobeka – Chairperson of the Education Sector Committee in the UNESCO National Commission

Dr Thato Chidarikire of the Department of Health

Ms Ruth Pooe of the Department of Social Development Dr Granville Whittle, Deputy Director-General at DBE Senior Government Officials

Representatives of Civil Society, Stakeholders and Partners Teachers, Learners, Young People

Sanibonani

It’s a pleasure be afforded the opportunity to address this one-of-a-kind launch, co-led with the five UN Agencies: UNAIDS, UNESCO, UNFPA, UNICEF and UN Women. It is interesting to note that all 5 of these agencies are led by women, working with the Ministry of Basic Education that is also led by women, the Minister and myself as the Deputy Minister. The UN Family is clearly sharing with the Department’s gender transformational agenda. The work that we do together intends to respond to the needs of adolescent girls and young women to enjoy the full benefit of education as the key for unlocking the potential emancipation from structural drivers of HIV infection; early and unintended pregnancy; and gender-based violence and Femicide. Whilst all young people are deemed vulnerable, the prevailing gender inequality in our society places adolescent girls and young women at greater risk of HIV and GBVF. The circumstantial challenges to girls impede on their school completion, which often extends to the school-to-work transition.

You would have noted in the invitations to this occasion that the ‘Education Plus’ Initiative is regarded as a high-profile, high-level political advocacy drive to accelerate actions and investments to prevent HIV. It is centred on the empowerment of adolescent girls and young women, and the achievement of gender equality in sub-Saharan Africa — with secondary education as the strategic entry point.

It responds to the urgency required to effectively address the alarming numbers of adolescent girls and young women heavily affected by HIV infection, early unintended pregnancy and gender-based violence and femicide, which affect their survival, well-being, human rights and fundamental freedoms.

This multi-sectoral initiative represents a rights-based, gender-responsive action agenda for adolescent girls and young women to lead healthy, secure and fulfilling lives while paving their way to vibrant futures. The rewards will be far- reaching into the longer-term, with inter-generational effects. This work is premised on the belief that empowered girls are the empowered women of the future. Within the South African context, we have been very clear with our stakeholders and partners that whilst the focus is predominantly for the adolescent girls and young women, we do not leave the boy child behind, as well as our children of diverse sexual and gender identities. If we want to level the playing field for gender equality to flourish, we have to implement deliberate interventions to impact the entire gender spectrum.

As the government, we are fully aware that the Economic Reconstruction and Recovery Plan depends on a healthy adult population, flourishing learners in proper schools and the vulnerable being cushioned from the ravages of poverty and neglect. And so, to ensure economic transformation, a systems approach is required where no child is left behind. The National Strategic Plan on HIV, TB and STIs highlights the importance of focused interventions directed at young people, especially adolescent girls and young women between the ages of 15 and 24.

The inclination towards young women and girls is adopted in response to the fact that women and girls are biologically more susceptible to HIV than men and boys. More so, unequal gender power dynamics and harmful gender norms, compounded by the intersecting forms of discrimination, are mostly felt by women, girls and children of diverse sexual and gender identities.

Programme Director, another endemic of concern is the relentless gender- based violence that disproportionally affects women and girl children. Despite the concerted efforts in addressing gender-based violence in the country, this problem is tough to address, especially in schools, because the root causes are rooted in households and communities. Ongoing instances of femicide have been reported, with some deaths committed in the most heinous manner imaginable.

The perpetrators are mostly men and boys who have suffered the most traumatic experiences of boyhood and manhood that have completely shifted their humanity for the worst. So, we need to be intentional in our efforts to work with our partners in conceptualizing and nurturing programmes that help us impact on the boy child form an early age. This will help us ensure that “re e koba e sa le metsi” (we bend the reed while it is still wet).

It is no coincidence, colleagues; that in South Africa, we are launching this Initiative within the month of March. A month embodied with two key celebrations: the International Women’s Day and Human Rights Day; both symbolic to our cause. More interestingly, our Sister Department of Home Affairs is celebrating this day as the Transgender Day of Visibility towards creating a safe and inclusive space for transgender people to enjoy their constitutionally given rights. So as we close off the month with all these significant days, we are also opening with our UN Family a new chapter of intent:

intent to ensure that we unite the comparative advantages and contributions of the UN agencies and their vast network of partners, joined up around one shared vision and ambitious objective for high impact advocacy and mobilization; intent to ensure that primary schooling is accessible and welcoming to all children, irrespective of sexual and gender identity, circumstances, character and background so that our schools become socially cohesive and inclusive in preparation for a seamless transition to secondary education; and intent to ensure that this launch helps us to reach the desires and objectives for the rights, dignity, realisation and completion of secondary schooling for all children, especially adolescent girls and young women.

Esteemed Guest, as government, we do not need any policy harmonization or shift. We are one of SADC member states using the operational framework of Care and Support for Teaching and Learning (CSTL); which allows us to mainstream care and support in the different key priority areas. As such, within this framework, the Integrated School Health Programme (ISHP), implemented with the Department of Health and the Department of Social Development, allows us an opportunity with our social partners to use schools as vehicles for promoting access to a range of public services in areas such as health, poverty alleviation, psychosocial support, sport and culture. Whilst health screening is essential for learners’ health and well-being, linking them to services to address the identified health barriers is even more important.

On the 17th of February, we launched the progressive Policy for the Prevention and Management of Learner Pregnancy; another enabling policy that allows us to work towards creating an inclusive and supportive schooling environment that is capable, proactive, preventative, caring and supportive to young girls and mothers.

The Learner Pregnancy Policy Launch came at a critical time as the country reported over a hundred and thirty-two thousand (132 000) pregnancies amongst 10 – 19 year olds in the 2020 – 2021 financial year.

This statistic is most alarming because research indicates that one in three pregnant girls will not return to school. To tip the scales further, girl children who do not return to school, may fall victim of more subsequent pregnancies. In reality, we know that 2020 was the time when COVID-19 hit our shores with strict control measures set in place to reduce the spread of the pandemic.

Yet, researchers and monitors reported that children and families experienced the most sexual abuse, gender-based violence, domestic violence and other forms of violence and discrimination. It was a terrible way to assert with members of the public that in actual fact children are better off in schools, in a controlled environment. Our big task is to ensure that while they are in that school catchment, we intensify provision of essential services, in and through schools. Our policy framework supports holistic development of children whilst they are in school; not only in literacy and numeracy but also, socially and among their peers; to empower them to make informed decisions about their sexuality, their lives, their health and wellbeing.

Dr Wanda Draper, in her seminal work, Your Child is Smarter than You Think, explains the approach to holistic development of children and says:

“You can’t send the head to school and leave the body at home—the whole child goes to school, the whole child lives at home, and the whole child participates in the world.”

This means that their schools must better prepare them to read, write, count, and think critically, including; identifying any health barriers that could potentially impede their chances to attend school, remain in school and finish school to the best of their ability. I look forward to the message and responses from the Youth Representative of SANAC and the responses that the learners will give today. It is clear that our future is in safe hands and that our education system is indeed, developing a whole child, a young person fit to compete with the best in the world. Yes, we know that the core mandate of the Department of Basic Education is the delivery of Curriculum… but imagine a school with no health support – no access to the health screening for TB, HIV and sexual reproductive health, for instance.

Imagine a school full of hungry children without nutritional support for those learners who display the intersecting vulnerabilities, including poverty. A school with no school sport, arts and cultural activities. Imagine, Colleagues, a school in a democratic State like South Africa, but which does not advocate for social inclusion and cohesion, with no care for the often marginalised and vulnerable key populations.

The work that we are about to embark on with the UN Agencies is regarded as work of soft issues, but it has the potential of altering a child’s life. We should not trivialise or take this work for granted.

So I hope that what emerges from this Launch will strengthen and support the already-existing programmes within the sector and nurture those that require improvement of efficiencies. We should pay particular emphasis to evidence- based programmes that were crippled by COVID-19

In conclusion, I wish to call upon all other stakeholders to join this initiative and in our collective efforts; and make this ambitious initiative a reality. On behalf of the Department of Basic Education, I wish to accept the support we are receiving from the UN Agencies and further declare our commitment to collaborate and cooperate with you for the greater benefit of the child.

Source: Government of South Africa

President Cyril Ramaphosa announces new National Commissioner of Police, 31 Mar

President Cyril Ramaphosa will announce the new National Commissioner of Police in an address to the nation at 16h30 today, Thursday, 31 March 2022.

The President’s appointment of a new National Commissioner will ensure continuity in the most senior position in the South African Police Service following the departure from office today of National Commissioner Khehla Sitole.

The President’s address will be broadcast and streamed live on the major news channels and PresidencyZA online and social platforms.

Source: Government of South Africa

YOFC Announces 2021 Annual Results

Proportion of Overseas Business Exceeds 30% for the First Time

Net Profit Reaches 710 Million Yuan, Up 30% YoY

WUHAN, China, March 30, 2022 /PRNewswire/ — Yangtze Optical Fibre and Cable Joint Stock Limited Company (hereinafter referred to as “YOFC” or “the Company”) has recently announced its consolidated results for 2021 (the “Reporting Period”). During the reporting period, operating revenue reached 9,536 million yuan, an increase of 16.0% from 2020. Net profit attributable to shareholders of the parent company stood at 710 million yuan, up 30.3% YoY.

During the reporting period, YOFC continued to optimize production efficiency and cost structure, expanded the application scenarios of new products, and consolidated its leadership in the global optical Fibre and cable markets. A point of success in terms of technological innovation defined by achieving full autonomy across the whole of the optical Fibre value chain, the Company strengthened the R&D of new optical Fibres, resulting in it being the first worldwide to roll out dispersion-flat Fibre for 5G forward transmission. In another first, the Company’s large-effective-area Fibres with ultra-low attenuation as well as its proprietary multi-core and low-mode Fibre lead globally. Furthermore, the Company’s high-end multi-mode optical Fibre is being widely used in the construction of large-scale data centers at home and abroad.

While ensuring the core advantages of the main business, YOFC has continuously accelerated the pace of diversification and achieved breakthroughs in many fields. The Company has further enhanced its portfolios for optical modules/optical devices, communication network engineering, data center wiring as well as active optical cables for consumer electronics applications, while achieving new growth in optical modules, semiconductor quartz materials and submarine communications cables. The company has further leveraged its advantages in optical modules and optical devices, to avail itself of project opportunities in the data center and communication markets, with this segment demonstrating a new jump in revenue during the reporting period.

In 2021, YOFC rolled out a roadmap focused on further differentiation of products and services to enhance international competitiveness and establish a wider presence across existing and new markets. An examination of product demand and potential profitability in several target markets, most notably in Southeast Asia, Africa and Latin America, became the basis of a plan to expand production capacity accordingly, resulting in the rapid growth of overseas business revenue. During the year, the company achieved the first milestone of the new roadmap, when business revenue ex-China reaching 310 million yuan, up 46.8% YoY and accounted for more than 30% of annual revenue for the first time. Two significant projects that contributed to reaching the milestone were communication network facilities in the Philippines and in Peru, where, in both cases, the teams in charge proved themselves capable of overcoming challenges presented by the COVID-19 pandemic and completed their construction targets on schedule. These two successes were recognized by local operators, leading to the garnering of follow-up project orders. In June 2021, the Company completed the acquisition of YOFC Poliron Indústria e Comércio de Cabos Especiais Ltda. (Poliron) in Brazil, establishing its first production facility in the region. In addition, in view of actual demand across Southeast Asia, Africa and Latin America, the Company expanded its optical Fibre and cable production capacity in Indonesia as well as its optical Fibre production capacity in Poland.

Looking forward into 2022, a year marked by both opportunities and challenges, YOFC expects to consolidate the worldwide leadership position of its main business by leveraging a need to rebalance supply and demand across the industry and to continue implementing key strategic initiatives. The Company is also planning the next stage of the globalization of operations by further enhancing the overseas production capacity portfolio, as well as reinforce overseas teams through hiring local talents, so that needs of customers can be better met by conversing with them in their native languages.

https://en.yofc.com/

Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorization

Risk of symptomatic COVID-19 was reduced by 71% compared to placebo in pre-exposure prophylaxis and 75% compared to placebo in post-exposure prophylaxis

Risk of hospitalization or death in participants with mild to moderate COVID-19 was reduced by 66% compared to placebo in the primary efficacy analysis population and by 77% compared to placebo in participants who received treatment within three days of symptom onset

Full year and fourth quarter 2021 financial results reported; $591 million in cash and investments expected to be sufficient to fund operations into second half of 2024

WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases, reported that the primary endpoints were met with statistical significance for all three indications in the company’s ongoing global Phase 2/3 clinical trials evaluating its investigational drug adintrevimab (ADG20) as a pre-and-post-exposure prophylaxis (EVADE) and treatment (STAMP) for COVID-19. EVADE and STAMP were primarily conducted during a time when pre-Omicron SARS-CoV-2 variants were dominant. Following the emergence of the Omicron variant, in a pre-specified exploratory analysis in a subset of the pre-exposure cohort, a clinically meaningful reduction in cases of symptomatic COVID-19 was observed with adintrevimab compared to placebo. Across both trials, a single intramuscular (IM) administration of adintrevimab at the 300mg dose had a similar safety profile to that of placebo. Based on these data, Adagio plans to engage with the U.S. Food and Drug Administration (FDA) and to submit an Emergency Use Authorization (EUA) application in the second quarter of 2022 for adintrevimab for both the prevention and treatment of COVID-19.

In addition, Adagio provided an update on its ongoing Phase 1 study evaluating adintrevimab at higher doses and on research activities related to adintrevimab re-engineering and the identification of new antibodies to potentially address COVID-19 and other viruses.

“COVID-19 continues to pose significant challenges globally as waning immunity combined with the emergence of resistant variants has led to ongoing waves of disease. We believe that a suite of options – spanning prophylaxis and treatment – is needed to effectively address this virus as it continues to evolve, and these data give us confidence in the potential role adintrevimab can play in physicians’ arsenals,” said David Hering, MBA, interim chief executive officer and chief operating officer of Adagio. “Based on the data from both EVADE and STAMP, including the impacts observed in preliminary analyses from participants enrolled after the emergence of the Omicron variant, our team is initiating discussions with the FDA and preparing an EUA submission for adintrevimab. With more than one million doses of adintrevimab secured for 2022 and a solid financial position expected to take us into the second half of 2024, we are optimistic about the road ahead and the impact adintrevimab could have for the many people around the globe, particularly those at high risk with co-morbidities, who continue to need options.”

Michael Ison, M.D., M.S., professor of Medicine in the Division of Infectious Diseases and of Surgery in the Division of Organ Transplantation, Northwestern University Feinberg School of Medicine, added, “the compelling data generated on adintrevimab in both of Adagio’s clinical trials represent an important step toward further addressing the continuation of the COVID-19 pandemic. I am particularly encouraged by the consistent treatment effect observed across all three clinical settings and patient subpopulations, and the favorable safety profile, with just a single dose and convenient IM delivery for all patients. The risk-reduction in the post-exposure prophylaxis setting regardless of serostatus translates to real-world use when clinicians might not know the vaccination or prior infection status of their patients. In the STAMP trial, adintrevimab showed prevention of hospitalization and death in the face of the ‘highest-risk’ variant (Delta) to-date.”

EVADE Preliminary Data
EVADE is a global, multi-center, double-blind, placebo-controlled Phase 2/3 clinical trial evaluating adintrevimab at the 300mg IM dose in two independent cohorts for the prevention of COVID-19. The study includes a pre-exposure prophylaxis (PrEP) cohort and a post-exposure prophylaxis (PEP) cohort. The study population is comprised of adults and adolescents at risk of SARS-CoV-2 infection due to reported recent exposure or whose circumstances placed them at increased risk of acquiring SARS-CoV-2 infection and developing symptomatic COVID-19.

In the primary efficacy analysis of the PrEP cohort, adintrevimab was associated with a lower incidence of symptomatic COVID-19 compared with placebo through month three or the emergence of Omicron, whichever was earlier (12/730, 1.6% vs. 40/703, 5.7%, respectively). The standardized risk difference was -4.0% (95% CI –6.0, -2.1; p <0.0001), demonstrating a 71% relative risk reduction in favor of adintrevimab through three months. There were five (0.7%) COVID-19 related hospitalizations in the placebo group compared to none in the adintrevimab group. In a pre-specified exploratory analysis of the PrEP cohort, which included 402 participants (196 and 206 in the adintrevimab and placebo groups, respectively) following the emergence of Omicron (BA.1), a clinically meaningful reduction in cases of symptomatic COVID-19 was observed with adintrevimab, as compared to placebo. Adintrevimab was associated with a relative risk reduction of 59% and 47% with a median follow-up duration of 56 and 77 days, respectively (nominal p <0.05).

In the primary efficacy analysis in the PEP cohort, adintrevimab met statistical significance and was associated with a lower incidence of symptomatic COVID-19 through day 28 compared with placebo (3/173, 1.7% vs. 12/175, 6.9%, respectively). The standardized risk difference was -4.9% (95% CI: -8.8, -1.0; p=0.0135), demonstrating a 75% relative risk reduction in favor of adintrevimab through 28 days. There were two (1.1%) COVID-19 related hospitalizations in the placebo group compared to none in the adintrevimab group.

In the EVADE cohorts across 1,239 adintrevimab-treated participants with a median range of follow up of 140 days for the PrEP cohort and 126 days for the PEP cohort as of the March 2, 2022, data cut off, the safety profile was similar to that of placebo. The incidence of adverse events (AEs), including serious adverse events (SAEs), was similar between adintrevimab and placebo groups. No study drug related SAEs, including deaths, were reported. The most frequently reported AEs were injection-site reactions, the majority of which were mild or moderate in severity and occurred with similar frequency in both groups.

STAMP Preliminary Data
STAMP is a global, multi-center, double-blind, placebo-controlled Phase 2/3 clinical trial evaluating adintrevimab at the 300mg IM dose in patients with mild to moderate COVID-19 who are at high risk for disease progression. Adintrevimab was associated with a statistically significant lower incidence of COVID-19 related hospitalization or all cause death through day 29 compared with placebo (8/169, 4.7% vs. 23/167, 13.8%), with a standardized risk difference of -8.6% (95% CI: -14.65, -2.57; p=0.0052), demonstrating a 66% relative risk reduction in favor of adintrevimab. There was one death (0.6%) in the adintrevimab group, compared with six deaths (3.6%) in the placebo group through day 29. In patients treated within three days of symptom onset (adintrevimab n=91, placebo n=85), adintrevimab reduced the risk of COVID-19 hospitalization or death from any cause by 77% compared to placebo. STAMP enrolled 63 participants (29 in the adintrevimab group and 34 in the placebo group) with COVID-19 infection with the Omicron SARS-CoV-2 variant. There were two events of COVID-19 related hospitalization and no deaths through day 29 among the patients with the Omicron variant, and both events of hospitalization occurred in the placebo group.

In STAMP, across 192 adintrevimab-treated participants with a median follow up of 73 days in the adintrevimab group as of the February 2, 2022, data cut off, the incidence of AEs, including SAEs, was lower in the adintrevimab group. No study drug related SAEs, including deaths, were reported. The most frequently reported AEs were injection-site reactions, all of which were mild or moderate in severity and occurred with similar frequency in both groups.

“On behalf of the entire Adagio team, I’d like to thank the numerous investigators, clinical teams and, most importantly, the patients, families and caregivers for their participation in our clinical trials. We are encouraged by the data and look forward to submitting an EUA and discussing these results with the FDA and other regulatory authorities. Further, we are continuing our research efforts to improve adintrevimab activity against Omicron and identify antibodies targeting novel domains, which will provide potential additional product candidates to take into clinical development. Collectively, these efforts showcase the ability of our platform and expertise to discover, design and engineer novel antibodies, and execute global clinical trials, to potentially address infectious diseases,” said Ellie Hershberger, Pharm.D., chief development officer of Adagio.

Additional Development and Research Updates
Adagio continues to leverage its platform and expertise by conducting numerous efforts to address COVID-19, other coronaviruses, influenza and other infectious diseases, including:

  • Advancing a Phase 1 trial in healthy volunteers to evaluate pharmacokinetics and safety of additional higher doses of adintrevimab to supplement the data generated to date, which has evaluated doses up to 600mg IM. Preliminary safety data through two weeks post-dosing suggest a favorable safety profile at the 1200mg dose administered with IM injection or intravenously (IV).
  • Ongoing efforts to modify adintrevimab to improve binding to the Omicron subvariants (BA.1 and BA.2) in order to enhance neutralization potency while retaining the broad neutralization observed in vitro against other SARS-CoV-2 variants of concern. Re-engineered variants of ADG20 show over 100-fold improvement in binding and up to 40-fold enhanced neutralizing activity against the Omicron BA.1 variant while maintaining activity against all other variants of concern tested to date.
  • Ongoing discovery efforts to assess additional monoclonal antibodies from the company’s proprietary library of previously isolated SARS-CoV-2 antibodies for neutralization breadth and potency, which could be developed as a standalone treatment or combination therapy. Novel antibodies isolated from Omicron breakthrough infection donors have displayed in vitro activity against the 2003 SARS virus and all SARS-CoV-2 variants of concern tested to date, including the BA.1 and BA.2 variants.
  • Continuing discovery efforts to identify novel, broadly neutralizing antibodies that target epitopes both within and outside the receptor binding domain of SARS-CoV-2 and pan betacoronavirus neutralizing antibodies.

Full Year and Fourth Quarter 2021 Financial Results

  • Cash Position and Financial Guidance: Cash, cash equivalents and marketable securities were $591.4 million as of December 31, 2021. Based on current operating plans, Adagio expects its existing cash, cash equivalents and marketable securities will enable the company to fund its operating expenses and capital expenditure requirements into the second half of 2024.
  • R&D Expenses: Research and development (R&D) expenses, including in-process research and development expenses, were $68.4 million for the quarter ended December 31, 2021, and $190.4 million for the year ended December 31, 2021.
  • SG&A Expenses: Selling, general and administrative (SG&A) expenses were $14.7 million for the quarter ended December 31, 2021, and $36.5 million for the year ended December 31, 2021.
  • Net Loss: Net loss was $83.0 million, or $0.77 basic and diluted net loss per share, for the quarter ended December 31, 2021, and $226.8 million, or $5.32 basic and diluted net loss per share, for the year ended December 31, 2021.

About Adintrevimab
Adintrevimab (ADG20), Adagio’s lead product candidate, is designed to be a potent, broadly neutralizing antibody for both the prevention and treatment of COVID-19, including disease caused by most variants, as either a single or combination agent. Adintrevimab is being assessed in two separate Phase 2/3 clinical trials: the EVADE trial for the prevention of COVID-19 in both the post-exposure and pre-exposure settings, and the STAMP trial for the treatment of COVID-19. Preliminary data from these trials demonstrated that in the pre-Omicron population, adintrevimab met the primary endpoints across all three indications, demonstrating statistically significant and clinically meaningful efficacy. Across each of the trials, intramuscular (IM) administration of adintrevimab at the 300mg dose had a similar safety profile to that of placebo. Adintrevimab is also being evaluated in a Phase 1 study to evaluate safety and pharmacokinetics at higher doses, and as of an interim data cut, no study drug related adverse events, serious adverse events, injection-site reactions or hypersensitivity reactions were reported across all dose levels evaluated. Adintrevimab is an investigational monoclonal antibody that is not approved for use in any country. The safety and efficacy of adintrevimab have not been established.

About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases. The company is developing its lead product candidate, adintrevimab, for the prevention and treatment of COVID-19, the disease caused by the virus SARS-CoV-2 and its variants. Beyond COVID-19, Adagio is leveraging robust antibody discovery and development capabilities that have enabled expedited advancement of adintrevimab into clinical trials to develop therapeutic or preventative options for other infectious diseases, such as additional coronaviruses and influenza. Adintrevimab is an investigational monoclonal antibody that is not approved for use in any country. The safety and efficacy of adintrevimab have not been established. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “could”, “expects,” “intends,” “potential”, “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of adintrevimab, the review and analysis of data from our ongoing trials and the timing thereof, the initiation, modification and completion of studies or trials and related preparatory work, and our research and development programs; our plans related to engaging with regulatory authorities, including the timing of any regulatory submissions or applications; our pursuit of other strategies to broaden our portfolio of SARS-CoV-2 mAbs to address other SARS-CoV-2 variants of concern, including the Delta and Omicron variants; our discovery efforts to identify novel broadly neutralizing antibodies that target distinct epitopes both within and outside the receptor binding domain of SARS-CoV-2 and other beta coronaviruses; our expected cash runway; and other statements that are not historical fact. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, the impacts of the COVID-19 pandemic on our business and those of our collaborators, our clinical trials and our financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, the predictability of clinical success of adintrevimab based on neutralizing activity in pre-clinical studies, variability of results in models used to predict activity against SARS-CoV-2 variants of concern, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, and the uncertainties and timing of the regulatory approval process, including the outcome of our discussions with regulatory authorities concerning our Phase 2/3 clinical trials and the result of any emergency use application submission. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in Adagio’s Form 10-Q for the quarter ended September 30, 2021 filed with the Securities and Exchange Commission (the “SEC”), and in our other filings with the SEC, and in Adagio’s future reports to be filed with the SEC. Such risks may be amplified by the impacts of the COVID-19 pandemic.  Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts
Media Contact:
Dan Budwick, 1AB
[email protected]

Investor Contact:
Monique Allaire, THRUST Strategic Communications
[email protected]

ADAGIO THERAPEUTICS, INC.
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(In thousands, except share and per share amounts)

December 31,
2021 2020
Assets
Current assets:
Cash and cash equivalents $ 542,224 $ 114,988
Marketable securities 49,194
Prepaid expenses and other current assets 25,293 2,394
Total current assets 616,711 117,382
Property and equipment, net 83
Other non-current assets 3,297
Total assets $ 620,091 $ 117,382
Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable $ 5,783 $ 8,153
Accrued expenses 56,277 4,919
Total current liabilities 62,060 13,072
Early-exercise liability 6 11
Other non-current liabilities 6
Total liabilities 62,072 13,083
Commitments and contingencies
Convertible preferred stock (Series A, B and C), $0.0001 par value; no shares authorized, issued and outstanding at December 31, 2021; 12,647,934 shares authorized, issued and outstanding at December 31, 2020; aggregate liquidation preference of $0 and $169,900 at December 31, 2021 and December 31, 2020, respectively 169,548
Stockholders’ equity (deficit):
Preferred stock (undesignated), $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding at December 31 2021; no shares authorized, issued and outstanding at December 31, 2020
Common stock, $0.0001 par value; 1,000,000,000 shares authorized, 111,251,660 shares issued and 110,782,909 shares outstanding at December 31, 2021; 150,000,000 shares authorized, 28,193,240 shares
issued and 5,593,240 shares outstanding as of December 31, 2020
11 1
Treasury stock, at cost; 468,751 shares and 22,600,000 shares at December 31, 2021 and December 31, 2020, respectively (85 )
Additional paid-in capital 850,125 154
Accumulated other comprehensive loss (8 )
Accumulated deficit (292,109 ) (65,319 )
Total stockholders’ equity (deficit) 558,019 (65,249 )
Total liabilities, convertible preferred stock and stockholders’ equity (deficit) $ 620,091 $ 117,382

ADAGIO THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
(In thousands, except share and per share amounts)

Year Ended
December 31, 2021
Period from
June 3, 2020
(Inception) to
December 31, 2020
Operating expenses:
Research and development(1) $ 182,891 $ 21,992
Acquired in-process research and development(2) 7,500 40,125
Selling, general and administrative 36,517 3,210
Total operating expenses 226,908 65,327
Loss from operations (226,908 ) (65,327 )
Other income (expense):
Other income (expense), net 118 8
Total other income (expense), net 118 8
Net loss (226,790 ) (65,319 )
Other comprehensive income (loss):
Unrealized loss on available-for-sale securities, net of tax (8 )
Comprehensive loss $ (226,798 ) $ (65,319 )
Net loss per share attributable to common stockholders, basic and diluted $ (5.32 ) $ (18.10 )
Weighted-average common shares outstanding, basic and diluted 42,621,265 3,608,491

(1)  Includes related-party amounts of $4,150 for the year ended December 31, 2021 and $595 for the period from June 3, 2020 (inception) to December 31, 2020.
(2)  Includes related-party amounts of $7,500 for the year ended December 31, 2021 and $39,915 for the period from June 3, 2020 (inception) to December 31, 2020.

Umit Ciftci Named Regional Business Development Manager for Turkey

TEMECULA, Calif., March 29, 2022 (GLOBE NEWSWIRE) — Nikkiso Cryogenic Industries’ Clean Energy & Industrial Gases Group (“Group”), a part of the Nikkiso Co., Ltd (Japan) group of companies, is pleased to announce that Umit Ciftci has been named Regional Business Development Manager for Turkey and the surrounding areas.

Based in Istanbul Turkey, he will be responsible for the Group’s full product line, and will report to Ole Jensen, NCE&IG GmbH Germany.

Umit received a degree in Management Engineering, which provided a solid background in engineering as well as business and finance. He has over 25 years of experience in Compressed Air working at various positions including sales engineer, marketing and business line manager in Turkey and Business Development Manager in UAE for Atlas Copco.

“Umit’s experience, as well as market and industry knowledge will be of great benefit to NCEIG GmbH, as we work to develop the potential opportunities in this market. We look forward to his positive contributions,” according to Ole Jensen, Vice President NCEIG Europe.

With this addition, Nikkiso continues their commitment to be both a global and local presence for their customers.

ABOUT CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (now a member of Nikkiso Co., Ltd.) member companies manufacture engineered cryogenic gas processing equipment and small-scale process plants for the liquefied natural gas (LNG), well services and industrial gas industries. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Cosmodyne and Cryoquip and a commonly controlled group of approximately 20 operating entities.

For more information please visit www.nikkisoCEIG.com and www.nikkiso.com.

MEDIA CONTACT:
Anna Quigley
+1.951.383.3314
[email protected]

LeddarTech revela valor da fusão e percepção de dados brutos na Automotive Tech.AD Berlin (Alemanha) de 3 a 5 de abril de 2022

Tecnologia de percepção ambiental para uma condução autônoma mais segura com detecção melhor

QUEBEC CITY, March 29, 2022 (GLOBE NEWSWIRE) — A LeddarTech®, líder global no fornecimento da tecnologia de detecção ADAS e AD mais flexível, robusta e precisa, tem o prazer de anunciar sua participação na Automotive Tech.AD Berlin no Titanic Chaussee Hotel Berlin como expositora e palestrante principal.

4-5 de abril de 2022: LeddarVision™ Demonstrator Space da LeddarTech (ao vivo e virtual)

Junte-se à equipe da LeddarTech para demonstrações reais de LeddarVision. O único software de fusão e percepção de sensores que usa fusão de dados brutos para simplificar conjuntos de sensores complexos, eliminar a dependência de hardware e fornecer aos clientes a flexibilidade de soluções de escala rápida em todos os modelos de veículos, proporcionando maior desempenho de ADAS e AD.

Conheça o CTO da LeddarTech, Pierre Olivier, pioneiro em sensoriamento com mais de 30 anos de experiência que fará apresentações nesses eventos durante a conferência:

  • Domingo, 3 de abril de 2022, 19h45 – 23h CET: Sessão Informal

Tema: O Caminho para a Automação Plena – Progresso e Desafios

  • Segunda-feira, 4 de abril de 2022, 10h – 10h30 CET: Apresentação

Tema: Tecnologia de Detecção e Percepção – Soluções que Resolvem Desafios Críticos de Detecção

Conheça a LeddarVision, uma plataforma de fusão e percepção de sensores de dados brutos que gera um modelo ambiental 3D RGBD abrangente com suporte a múltiplos sensores para configurações de câmera, radar e LiDAR. Esta solução centrada em software oferece desempenho de percepção superior por meio de planejamento de caminho, detecção de espaço livre e detecção, rastreamento e classificação aprimorados de objetos.

Sobre a Automotive Tech.AD Berlin

A Tech.AD Europe estimula você com novas ideias, conexões e inspiração. Este evento é dirigido a engenheiros e especialistas automotivos avançados de OEMs, fornecedores de soluções e institutos de pesquisa líderes com foco na aprendizagem de máquina AI +, tecnologias de percepção e sensor, arquiteturas de software e plataformas AV, testes e validação, veículos comerciais e implantação antecipada, conectividade e 5G, infraestruturas e cidades inteligentes, segurança e proteção, e muito mais. Junte-se a mais de 500 dos especialistas e executivos de veículos autônomos técnicos mais influentes em Berlim e online! Participe do evento também juntamente com a LeddarTech pessoalmente ou de forma digital registrando-se hoje mesmo no https://www.autonomous-driving-berlin.com/.

Sobre a LeddarTech

Fundada em 2007, a LeddarTech é uma empresa abrangente de sensoriamento ambiental completo, que viabiliza que os clientes resolvam desafios essenciais de sensoriamento, fusão e percepção em toda a cadeia de valor. A LeddarTech fornece soluções de percepção escaláveis econômicas de Nível 2+ ADAS ao Nível 5 de plena autonomia com LeddarVision™, uma plataforma de fusão e percepção de sensores de dados brutos que gera um modelo ambiental 3D abrangente a partir de uma variedade de tipos e configurações de sensores. A LeddarTech também dá suporte aos fabricantes LiDAR e integradores de sistemas automotivos de Nível 1-2 com o LeddarSteer™ de direção de feixe digital e o LiDAR XLRator™, uma solução para desenvolvimento LiDAR de estado sólido de grau automotivo com base na LeddarEngine™, e componentes principais de parceiros globais de semicondutores. A empresa é responsável por muitas inovações de aplicações com sensor remoto automotivos e de mobilidade avançadas, com mais de 100 tecnologias ADAS aprimoradas patenteadas (concedidas ou pendentes), e capacidade de condução autônoma.

Para mais informação sobre a LeddarTech, visite www.leddartech.com, LinkedIn, Twitter, Facebook e YouTube.

Contato:
Daniel Aitken, Vice-Presidente, Marketing Global, Comunicações e Relacionamento com o Investidor, LeddarTech Inc.
Tel.: + 1-418-653-9000 ramal 232
[email protected]

Contato de Relações com Investidores: InvestorRelation[email protected]
https://investors.leddartech.com/

Os logotipos Leddar, LeddarTech, LeddarSteer, LeddarEngine, LeddarVision, LeddarSP, LeddarCore, LeddarEcho, VAYADrive, VayaVision, XLRator e afins são marcas comerciais ou marcas comerciais registradas da LeddarTech Inc. e suas subsidiárias. Todas as outras marcas e nomes de produtos são ou podem ser marcas comerciais ou marcas comerciais registradas usadas para identificar produtos ou serviços de seus respectivos proprietários.